![]() | ![]() |
Formats:
|
||||||||||||
Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses 1Division of Infectious Diseases, Department of Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029, USA 2Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA 3NSF Center for Biophotonics Science and Technology, University of California Davis (UCD), Sacramento, CA 95817, USA 4Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA 95817, USA * To whom correspondence should be addressed. Email: ben.chen/at/mssm.edu Abstract The spread of HIV between immune cells is greatly enhanced by cell-cell adhesions called virological synapses, although the underlying mechanisms have been unclear. With use of an infectious, fluorescent clone of HIV, we tracked the movement of Gag in live CD4 T cells and captured the direct translocation of HIV across the virological synapse. Quantitative, high-speed three-dimensional (3D) video microscopy revealed the rapid formation of micrometer-sized “buttons” containing oligomerized viral Gag protein. Electron microscopy showed that these buttons were packed with budding viral crescents. Viral transfer events were observed to form virus-laden internal compartments within target cells. Continuous time-lapse monitoring showed preferential infection through synapses. Thus, HIV dissemination may be enhanced by virological synapse-mediated cell adhesion coupled to viral endocytosis. Human immunodeficiency virus (HIV) infection leads to depletion of CD4 T cells throughout the lymphoid system. Both cell-free and cell-associated infection routes contribute to viral dissemination in vivo (1). In vitro, infection with cell-associated HIV can be thousands fold more efficient than infection with cell-free virus (2), and inhibition of cell-cell contacts severely limits replication (3). Infection through synapses between virus-carrying dendritic cells and CD4 T cells is highly efficient (4, 5). For human T cell lymphotropic virus type I, viral synapses between T cells are essential for dissemination (6). For HIV, infected and uninfected CD4 T cells form virological synapses that organize viral receptors CD4, CXCR4, and Env (7). These infectious contacts are regulated by cell adhesion through integrins and intercellular adhesion molecules (8), dynamic actin and tubulin (9), cell signaling (10), and lipid raft recruitment (11). T cell virological synapses transfer virus with high efficiency (12), yet how this route fundamentally differs from cell-free infection remains unclear. To examine the spatial and temporal organization of synapse formation, we used an infectious, fluorescent HIV clone, carrying a Gag-internal, interdomain insertion of the green fluorescent protein (GFP), called HIV Gag-iGFP (13). This virus faithfully reveals Gag localization, allowing infected cells and viral particles to be tracked with high sensitivity (12). Time-lapse fluorescence microscopy of virological synapse formation showed that 24% of HIV Gag-iGFP–expressing Jurkat cells formed stable adhesions to primary CD4 T cells within 4 hours (Fig. 1 and table S1A). After adhesion, 80% formed focal Gag accumulations at the contact site with an average 82-min interval (Fig. 1, A and B). In contrast, an Env-deficient clone was unable to induce cell-cell conjugates or Gag accumulation (table S1B), illustrating that adhesion precedes Gag redistribution.
In fixed samples, high-resolution confocal imaging revealed prominent Gag accumulations at the synapse (Fig. 1C). In three-dimensional (3D) reconstructions, these appeared as button-shaped discs, 1 to 3 mm in diameter (Fig. 1D and movie S1). Synaptic buttons were also observed in HIV Gag-iGFP–expressing primary CD4 T cells cocultured with homologous primary CD4 cells (fig. S1). We assessed viral assembly at the synapse by measuring Gag oligomerization with fluorescence resonance energy transfer (FRET) (13–15) between Cerulean and Venus variants of HIV Gag-iGFP, which form a donor-acceptor FRET pair (16). Excitation of the Cerulean donor in cotransfected Jurkat cells generated a robust Venus-shifted FRET signal at synaptic buttons that is indicative of Gag homo-oligomerization (Fig. 1E). Photobleaching the Venus acceptor at a synapse lead to increased donor emission, providing additional evidence for FRET (Fig. 1, F to H, and fig. S2). Three-dimensional reconstruction of FRET images revealed concentrated Gag oligomerization at synapses (movie S2). With transmission electron microscopy, we observed that 100-nm budding viral crescents at the virological synapse protruded from the donor cell with bud tips directly abutting the target cell membrane (Fig. 1I). Viral buds were also observed far from the synapse, although at lower densities (fig. S3). Native, non–GFP-expressing HIV induced similar budding crescents, ruling out that GFP induced these accumulations (fig. S4). In thick 150-nm sections, near-complete viral buds and a virus-containing invagination in the synapsed target cell were observed (fig. S4, A and B). To capture the dynamics of Gag trafficking, reorganization, and viral transfer with higher temporal and spatial resolution, we recorded highspeed, spinning disc confocal fluorescence images. Forty-three putative synaptic events encompassing 1187 min revealed dynamic Gag movements during virological synapse formation (table S2). New synaptic button formation (n = 4) was captured where patches of membrane-associated Gag moved toward the cell adhesion site within minutes (Fig. 2A and movie S3). At existing buttons, a ring-shaped zone of Gag depletion often surrounded the synaptic button (Fig. 2B), indicative of a synapse-proximal region from which Gag was recruited.
HIV Gag-iGFP–labeled structures (n = 8) close to existing buttons moved rapidly and directionally into the button (Fig. 2C, fig. S5, and movies S4 to S6). The structures moved into the synapse with average velocities of 0.10 to 0.25 mm/s and peaks up to 0.8 mm/s (Fig. 2C and fig. S5). Other small, mobile Gag puncta emerged from and then moved back into the synaptic button (Fig. 2D and movie S7). The fast, directional movement of Gag was seen predominantly from nearby puncta. During cell-to-cell viral transfer (n = 10, table S2), fluorescent Gag signal protruded from buttons, penetrated the attached target cell, was released into the target cell, and then migrated distally with a mean velocity of 0.12 μm/s (Fig. 2E and movie S8). Notably, puncta 1.5 μm in diameter were observed (fig. S6A), and on occasion an entire synaptic button was transferred (movie S9). Large vesicular structures were also observed to fractionate into smaller vesicles while moving toward the distal pole of the cell (movies S4 and S8). The size of these translocated puncta exceeds individual clathrin- or caveolin-associated structures, which are uniformly small (100 to 200 nm) (17). By using quantitative confocal microscopy, we found that the accumulation and maintenance of Gag puncta in target cells was remarkably stable over time (fig. S6, B to D, and movie S10). The GFP signal in flow-sorted HIV+ CD4 target cells was uniformly punctate, without evidence of syncitia, and confocal imaging suggested that puncta were not surface-associated (fig. S7). Anti-Env staining of the Gag-iGFP puncta required cell permeabilization, indicating that Env was present in an internal Gag+ compartment (Fig. 2, F and G). Transmission electron microscopy of the target cells revealed multivesicular structures, which were not seen in control, unexposed cells, that contained viruslike densities inside 1- to 2-mm compartments (Fig. 2H). We conclude that synapses target HIV into vesicular compartments within recipient cells. To track the fate of cells after synapse formation, we performed continuous, long-duration imaging. Jurkat donor cells were cotransfected with HIV Gag-iGFP and HIV NL-GI, an HIV molecular clone that expresses GFP in place of the viral early gene nef (18). This approach can visualize viral transfer (as puncta), as well as productive infection (as diffuse GFP) in the target cell. In example one, the infected cell synapsed with the target cell for 18 hours, the cells separated, and at 32 hours a diffuse, bright GFP signal indicated productive infection (Fig. 3, A C, and movie S11). Bystander target cells remained negative. Over 67 hours, 112 conjugates tracked resulted in seven productively infected MT4 target cells (table S3). In five cases, synapses were observed, and in four cases virus transfer was recorded (Fig. 3, A to C, and movie S12). Under culture conditions that limited new cell-cell interactions, productively infected cells arose preferentially after observed virological synapse events.
Because synapse-mediated viral transfer is coreceptor-independent (12, 19), we tested whether infection through T cell synapses requires coreceptor expression. Infection of MT4 cells by cell-associated HIV was inhibited when cells were separated by a 0.4-μm transwell barrier (Fig. 4A). Under these contact-dependent infection conditions, productive infection by cell-associated HIV NL-GI was inhibited by CXCR4-antagonist, AMD3100 (Fig. 4B). Furthermore, productive infection by cell-associated R5-tropic virus HIV NL-GI (JRFL) was dependent on expression of the chemokine receptor, CCR5 (Fig. 4C). The results suggest that infection through T cell synapses does not bypass the coreceptor requirement.
Synapse-mediated viral transfer is potently inhibited by actin inhibitors such as cytochalasin D (9, 12). We find that cytochalasin D had little effect on cell-free HIV infection yet effectively inhibited productive infection by cell-associated HIV (Fig. 4D). Additionally, a well-characterized patient antisera, which can potently block cell-free infection but not transfer of virus through virological synapses (12), did not efficiently block infection of the homologous cell-associated virus (Fig. 4E). Thus, inhibitor studies clearly distinguish the mechanisms of cell-free from those of cell-associated infection. The live imaging of HIV cell-to-cell transfer reveals that dynamic Gag movements in infected cells organize Gag puncta into synaptic buttons from which HIV is directly transferred into adjacent target cells. Although endocytic entry of cell-free HIV contributes only modestly to productive infection (20–22), our results suggest that the cell-to-cell transmission could favor endocytic routes. Thus when spreading via synapses, it is possible that HIV resembles a majority of viruses that enter preferentially through endocytosis (e.g., influenza, adenoviruses, picornaviruses, alphaviruses) (23). Given this scenario, the tight coupling of Env fusogenicity with particle maturation (24, 25) may activate viral fusion within a target cell compartment that is cloistered from neutralizing antibodies (12). Alternatively, the prominent endocytic process that accompanies synapse formation may create viral reservoirs in intracellular compartments. Future vaccine strategies may be focused against unique cell-surface Env epitopes that block cell-associated infection, and future antiviral drugs may target factors required for synapse formation. Ultimately the dynamics of virological synapse formation must be understood within lymphoid tissues, where high density and lymphocyte mobility (26) are likely to promote synaptic viral spread. Supplemental Online Material Click here to view.(4.2M, pdf) Acknowledgments We thank R. H. Cheng, V. Simon, M. Klotman, R. Iyengar, and A. Del Portillo for critiques and discussions; R. Huq for microscopy support; S. Izadmehr for image analysis; M. Grisotto and V. Sahi for cell sorting; H. Bell for electron microscopy support; and S. Lira for imaging support. Work was supported by NIH grant AI074420-02, Burroughs Wellcome Fund Investigator Award, and Hirschl Weill-Caulier Career Scientist Award to B.K.C. Imaging was supported by Mount Sinai School of Medicine–Microscopy Shared Resource Facility grants NIH-NCI 5R24 CA095823-04, NSF-DBI-9724504, and NIH-S10RR09145-01; by the NSF Center for Biophotonics Science and Technology (cooperative agreement PHY012099); a UCD Health System Research Award to T.H.; and the UCD Clinical and Translational Science Center grant NIH-NCRR ULRR024146 (T.H. and D.M.A.). References and Notes 1. Haase AT. Nat Rev Immunol. 2005;5:783. [PubMed] 2. Dimitrov DS, et al. J Virol. 1993;67:2182. [PMC free article] [PubMed] 3. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. J Virol. 2007;81:1000. [PMC free article] [PubMed] 4. Cameron PU, et al. Science. 1992;257:383. [PubMed] 5. McDonald D, et al. Science. 2003;300:1295. doi: 10.1126/science.1084238. published online 1 May 2003. [PubMed] [Cross Ref] 6. Igakura T, et al. Science. 2003;299:1713. doi: 10.1126/science.1080115. published online 13 February 2003. [PubMed] [Cross Ref] 7. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. J Exp Med. 2004;199:283. [PMC free article] [PubMed] 8. Jolly C, Mitar I, Sattentau QJ. J Virol. 2007;81:13916. [PMC free article] [PubMed] 9. Jolly C, Mitar I, Sattentau QJ. J Virol. 2007;81:5547. [PMC free article] [PubMed] 10. Sol-Foulon N, et al. EMBO J. 2007;26:516. [PMC free article] [PubMed] 11. Jolly C, Sattentau QJ. J Virol. 2005;79:12088. [PMC free article] [PubMed] 12. Chen P, Hubner W, Spinelli MA, Chen BK. J Virol. 2007;81:12582. [PMC free article] [PubMed] 13. Hubner W, et al. J Virol. 2007;81:12596. [PMC free article] [PubMed] 14. Derdowski A, Ding L, Spearman P. J Virol. 2004;78:1230. [PMC free article] [PubMed] 15. Larson DR, Ma YM, Vogt VM, Webb WW. J Cell Biol. 2003;162:1233. [PMC free article] [PubMed] 16. Rizzo MA, Springer GH, Granada B, Piston DW. Nat Biotechnol. 2004;22:445. [PubMed] 17. Lakadamyali M, Rust MJ, Zhuang X. Cell. 2006;124:997. [PMC free article] [PubMed] 18. Cohen GB, et al. Immunity. 1999;10:661. [PubMed] 19. Blanco J, et al. J Biol Chem. 2004;279:51305. [PubMed] 20. Fackler OT, Peterlin BM. Curr Biol. 2000;10:1005. [PubMed] 21. Marechal V, et al. J Virol. 2001;75:11166. [PMC free article] [PubMed] 22. Schaeffer E, Soros VB, Greene WC. J Virol. 2004;78:1375. [PMC free article] [PubMed] 23. Marsh M, Helenius A. Cell. 2006;124:729. [PubMed] 24. Wyma DJ, et al. J Virol. 2004;78:3429. [PMC free article] [PubMed] 25. Wyss S, et al. J Virol. 2005;79:12231. [PMC free article] [PubMed] 26. Germain RN, Miller MJ, Dustin ML, Nussenzweig MC. Nat Rev Immunol. 2006;6:497. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
Nat Rev Immunol. 2005 Oct; 5(10):783-92.
[Nat Rev Immunol. 2005]J Virol. 1993 Apr; 67(4):2182-90.
[J Virol. 1993]J Virol. 2007 Jan; 81(2):1000-12.
[J Virol. 2007]Science. 1992 Jul 17; 257(5068):383-7.
[Science. 1992]Science. 2003 May 23; 300(5623):1295-7.
[Science. 2003]J Virol. 2007 Nov; 81(22):12596-607.
[J Virol. 2007]J Virol. 2007 Nov; 81(22):12582-95.
[J Virol. 2007]J Virol. 2007 Nov; 81(22):12596-607.
[J Virol. 2007]J Cell Biol. 2003 Sep 29; 162(7):1233-44.
[J Cell Biol. 2003]Nat Biotechnol. 2004 Apr; 22(4):445-9.
[Nat Biotechnol. 2004]Cell. 2006 Mar 10; 124(5):997-1009.
[Cell. 2006]Immunity. 1999 Jun; 10(6):661-71.
[Immunity. 1999]J Virol. 2007 Nov; 81(22):12582-95.
[J Virol. 2007]J Biol Chem. 2004 Dec 3; 279(49):51305-14.
[J Biol Chem. 2004]J Virol. 2007 Jun; 81(11):5547-60.
[J Virol. 2007]J Virol. 2007 Nov; 81(22):12582-95.
[J Virol. 2007]Curr Biol. 2000 Aug 24; 10(16):1005-8.
[Curr Biol. 2000]J Virol. 2004 Feb; 78(3):1375-83.
[J Virol. 2004]Cell. 2006 Feb 24; 124(4):729-40.
[Cell. 2006]J Virol. 2004 Apr; 78(7):3429-35.
[J Virol. 2004]J Virol. 2005 Oct; 79(19):12231-41.
[J Virol. 2005]Nat Rev Immunol. 2006 Jul; 6(7):497-507.
[Nat Rev Immunol. 2006]